Gain Therapeutics
GANX | NASDAQ
$0.94
-$0.10 (-9.62%)
At close: Nov 16, 2026, 4:00 PM ET
$1.10
+$0.16 (+17.02%)
After-hours:
Nov 16, 2026, 6:40 PM ET
Gain Therapeutics Company Profile
Company profile explainedCompany Profile
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Key Executives
| Name | Position |
|---|---|
| Gene Mack | President, CEO, Director & Interim CFO |
| Terenzio Ignoni | Chief Operating Officer |
| Gianluca Fuggetta | Senior Vice President of Finance & Principal Financial Officer |
| Joanne Taylor | Chief Scientific Officer |
| Khalid Islam | Chairman & Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Oct 30, 2026 | 3 | Filing |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 17, 2026 | 4 | Filing |
| Jul 17, 2026 | 4 | Filing |
| Jul 17, 2026 | 4 | Filing |
Gain Therapeutics
| Country | United States |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Gene Mack |
Contact Details
4800 Montgomery Lane Bethesda,
Maryland 20814 United States
Stock Details
| Ticker Symbol | GANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819411 |
| CUSIP Number | 36269B105 |
| ISIN Number | US36269B1052 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove GANX